MARKET

RARX

Ra Pharms
RARX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-20.7349
709.67
8.65
2,271,549,355.63
About RARX
Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.
More

RARX News

More
Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ:APLS) announced that it expects to file a marketing application in H2 seeking app
seekingalpha · 05/21 16:20
How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry
Zacks · 04/01 13:26
Crash Protection Strategies II
Seeking Alpha - Article · 03/19 13:30
Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Business Wire · 02/28 12:00
Ra Pharmaceuticals EPS misses by $0.16
seekingalpha · 02/27 17:31
Ra Pharmaceuticals Q4 EPS $(0.79) Down From $(0.47) YoY
Ra Pharmaceuticals (NASDAQ:RARX) reported quarterly losses of $(0.79) per share. This is a 68.09 percent decrease over losses of $(0.47) per share from the same period last year.
Benzinga · 02/27 13:19
CRISPR Therapeutics Proposes Changes to the Board of Directors
GlobeNewswire · 02/26 21:05
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
Business Wire · 02/18 12:00

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Ra Pharms stock information, including NASDAQ:RARX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARX stock methods without spending real money on the virtual paper trading platform.